Microbot Medical (NASDAQ: MBOT) and Dermira (NASDAQ:DERM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.
This table compares Microbot Medical and Dermira’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Insider & Institutional Ownership
5.1% of Microbot Medical shares are held by institutional investors. Comparatively, 94.9% of Dermira shares are held by institutional investors. 31.8% of Microbot Medical shares are held by company insiders. Comparatively, 13.3% of Dermira shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of recent ratings and target prices for Microbot Medical and Dermira, as reported by MarketBeat.com.
||Strong Buy Ratings
Microbot Medical presently has a consensus price target of $1.75, indicating a potential upside of 133.33%. Dermira has a consensus price target of $32.71, indicating a potential upside of 265.93%. Given Dermira’s higher possible upside, analysts plainly believe Dermira is more favorable than Microbot Medical.
Valuation & Earnings
This table compares Microbot Medical and Dermira’s revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Microbot Medical has higher earnings, but lower revenue than Dermira.
Volatility & Risk
Microbot Medical has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500. Comparatively, Dermira has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
Dermira beats Microbot Medical on 7 of the 12 factors compared between the two stocks.
Microbot Medical Company Profile
Microbot Medical Inc., formerly StemCells, Inc., is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures. Its ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The Microbot SCS device is a robotic system designed as the ventricular catheter portion of a cerebrospinal fluid (CSF) shunt system. The Company’s TipCAT is an endoscope that provides see and treat capabilities within tubular lumens in the human body, such as the colon, blood vessels and the urinary tract.
Dermira Company Profile
Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.